Home/Pipeline/c-MYC Program

c-MYC Program

Oncology

Discovery/Hit-to-LeadActive

Key Facts

Indication

Oncology

Phase

Discovery/Hit-to-Lead

Status

Active

Company

Wayfinder Biosciences

About Wayfinder Biosciences

Wayfinder Biosciences is an early-stage biotech developing RNA-targeting small molecules to address undruggable disease targets. The company's platform integrates RNA-based sensors and AI/ML to discover compounds that bind to specific mRNA structures, halting protein production before it begins. Its initial pipeline focuses on high-value targets in oncology and neurodegeneration. As a private, pre-revenue company, Wayfinder is building its foundational platform and asset pipeline while seeking partnerships to expand into broader therapeutic areas.

View full company profile

Therapeutic Areas

Oncology Neurodegeneration

Other Oncology Drugs

Drug	Company	Phase	Status
Bi-XDC with PROTACs	Coherent Biopharma	IND-enabling	Active
Bi-XDC with RPT	Coherent Biopharma	Early-stage	Active
mRNA Anticancer Vaccine	Sunshine Biopharma	Preclinical Research	Active
Biosimilar Bevacizumab	Organon (2)	Phase 3	Active
Biosimilar Pembrolizumab	Organon (2)	Phase 3	Active
BCL-2 Inhibitor Program	Vincerx Pharma	Preclinical	Research
Not specified in provided content	3Sbio	Various	Active
Preclinical Projects	Zion Pharma	Preclinical	Active
Attenukine Oncology Candidate	Teva	Phase 1	Active
XEMA Tumor Marker ELISA Kit	XEMA Group	Commercial	Active
KRAS inhibitor	Risen Pharma Tech	Preclinical/Phase 1	Active (AACR 2024 presentation)
KEAP1 Activator Program	Vividion Therapeutics	Phase 1	Active